Specification
| Designation | PT-141 (bremelanotide) |
| Structure | Synthetic cyclic heptapeptide (alpha-MSH derivative) |
| Molecular weight | ≈1.03 kDa |
| Form | Lyophilized powder |
| Strength per vial | 10 mg |
| Box contents | 10 vials of identical strength (100 mg total) |
| Purity | ≥99 % (HPLC) |
Melanocortin receptors and signalling
Bremelanotide (PT-141) is a synthetic melanocortin receptor agonist characterised in laboratory work at MC1R, MC3R, MC4R and MC5R. The practical focus is MC3R and MC4R, which sit in the central and peripheral melanocortin system and take part in appetite regulation, energy balance and autonomic signalling. After agonist binding, G protein-coupled transduction typically raises cytosolic cAMP, so receptor activation and ligand potency can be read in matched assays. PT-141 is a defined reference ligand for binding kinetics, effect size and selectivity against other melanocortin peptides. Laboratories that buy PT-141 take bremelanotide at 10 mg per vial.
Reconstitution and handling
The lyophilizate is reconstituted in the laboratory with a suitable sterile solvent. The solvent is added slowly along the vessel wall and the preparation is mixed gently until the powder has dissolved fully. The resulting solution is processed promptly, because peptide solutions respond more readily to the surroundings than the dry material. Until use, the reagent is kept out of direct light. Volume and final concentration are set by the laboratory in its own protocol.
In vitro assays and model systems
In radioligand or fluorescence binding assays, researchers quantify the affinity of bremelanotide at membranes from cells that express MC3R or MC4R. cAMP accumulation assays and reporter-gene constructs show the downstream signal after receptor activation. Concentration-response curves with PT-141 as the agonist allow comparison with native melanocortin peptides and structurally related ligands. Neuronal and non-neuronal cell lines with a defined receptor status suit parallel reads of several MC subtypes in one series.
Quality and analytics
Each batch of PT-141 is tested for purity by HPLC, and the content is ≥99 %. An identity check confirms the cyclic heptapeptide scaffold of bremelanotide. Results are recorded per batch and apply to the offered 10 mg strength. This analytical profile supports reproducible measurement series in melanocortin receptor assays and the comparison of experiments across several laboratory runs.